CLINICAL TRIAL OF MEDICAL VS. SURGICAL TREATMENT OF VESICO-URETERAL REFLUX (VUR).

DOI: https://doi.org/10.1203/00006450-198404001-01679

IF: 3.953

1984-04-01

Pediatric Research

Abstract:VUR accounts for 15% of children and young adults with ESRD and it is a common cause of severe hypertension in the same population. Since 1980, we have conducted an international, prospective, randomized trial of early anti-reflux surgery (S) vs. medical therapy (M), namely, continous antibiotic chemoprophylaxis. The study population consists of children up to 10 years of age with primary VUR, grade IV/V (International Classification). The end points of the trial are: 1) renal growth, as measured by planimetry, 2) progression of renal scarring or development of new scars, 3) individual kidney GFR, as measured by DMSA renal scans, 4) rate of resolution of VUR in patients treated medically, 5) incidence of UTI, 6) incidence of hypertension. To date, 300 pts. have been enrolled. Preliminary analysis of the 116 USA pts. has yielded the following information: 42% of pts have at least 1 renal scar at entry; new or progressive scars were seen in 36% of M pts vs 50% of S pts when entry urograms were compared to those done 6 mo. later (p > .1). By 18 mo. of follow-up, grade IV/V VUR was still present in 83% of the pts in the M group. The incidence of acute pyelonephritis was 1 per 0.007 pt-months at risk in the S group, and 0.013 for M pts (p > .1). Only 1 pt has developed BP > 95th percentile for age and sex during 18 mo. follow-up. Six pts allocated to M have undergone anti-reflux surgery because of recurrent UTIs and 1 pt allocated to S has required re-operation for persistent VUR. Thus, no dramatic differences in course between M and S are apparent at this early analysis.

pediatrics